[Immuno-checkpoint inhibitor resistance and strategy in lung cancer]

Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):603-606. doi: 10.3760/cma.j.cn112147-20200312-00319.
[Article in Chinese]

Abstract

免疫检查点抑制剂通过启动并激活肿瘤内T细胞发挥抗肿瘤作用。但免疫系统在识别和杀伤肿瘤细胞的同时，也筛选出具有逃避免疫监视能力的肿瘤细胞，这一过程称为免疫编辑，该机制不仅存在于肿瘤的自然进程，也引起免疫检查点抑制剂的原发和继发性耐药，限制了该类药物在肺癌治疗中的临床应用。肿瘤细胞的抗原负荷、抗原提呈、肿瘤微环境中的免疫细胞浸润、细胞因子分泌、血管生成、代谢因素及肠道微生物群均与耐药有密切关系。深入研究肺癌免疫编辑的细胞学和分子生物学机制，有助于更深入理解免疫检查点抑制剂耐药的过程，并制定更适宜的治疗策略。.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • B7-H1 Antigen
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / pathology
  • China
  • Humans
  • Immunotherapy / methods*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / pathology
  • Precision Medicine
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology
  • Small Cell Lung Carcinoma / drug therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor